|Bid||89.71 x 1100|
|Ask||89.91 x 1200|
|Day's Range||88.79 - 89.92|
|52 Week Range||69.18 - 99.84|
|Beta (5Y Monthly)||0.43|
|PE Ratio (TTM)||29.08|
|Forward Dividend & Yield||3.09 (3.46%)|
|Ex-Dividend Date||Mar 03, 2020|
|1y Target Est||104.50|
Let's see if Novartis AG (NVS) stock is a good choice for value-oriented investors right now, or if investors subscribing to this methodology should look elsewhere for top picks.
Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Nov. 23) * AbbVie Inc (NYSE: ABBV) * Affimed NV (NASDAQ: AFMD) * ALX Oncology Holdings Inc (NASDAQ: ALXO) * Apellis Pharmaceuticals Inc (NASDAQ: APLS) * Atara Biotherapeutics Inc (NASDAQ: ATRA) * Beam Therapeutics Inc (NASDAQ: BEAM) * Cardiff Oncology Inc (NASDAQ: CRDF) * CareDx Inc (NASDAQ: CDNA) * Celldex Therapeutics, Inc. (NASDAQ: CLDX) * Cerevel Therapeutics Holdings Inc (NASDAQ: CERE) * Clearpoint Neuro Inc (NASDAQ: CLPT) * Corcept Therapeutics Incorporated (NASDAQ: CORT) * CTI BioPharma Corp (NASDAQ: CTIC) * Eidos Therapeutics Inc (NASDAQ: EIDX) * Fate Therapeutics Inc (NASDAQ: FATE) * Frequency Therapeutics Inc (NASDAQ: FREQ) * Galecto, Inc. (NASDAQ: GLTO) (appointed health care veteran Jayson Dallas to its board) * Inspire Medical Systems Inc (NYSE: INSP) * Keros Therapeutics Inc (NASDAQ: KROS) * Kronos Bio Inc (NASDAQ: KRON) * LeMaitre Vascular Inc (NASDAQ: LMAT) * Marinus Pharmaceuticals Inc (NASDAQ: MRNS) * Morphic Holding Inc (NASDAQ: MORF) * NeoGenomics, Inc. (NASDAQ: NEO) * Neuronetics Inc (NASDAQ: STIM) * NGM Biopharmaceuticals Inc (NASDAQ: NGM) * Nurix Therapeutics Inc (NASDAQ: NRIX) * Ocular Therapeutix Inc (NASDAQ: OCUL) * Olema Pharmaceuticals Inc (NASDAQ: OLMA) (debuted on Wall Street Thursday) * Organogenesis Holdings Inc (NASDAQ: ORGO) * Pacira Biosciences Inc (NASDAQ: PCRX) * PLx Pharma Inc (NASDAQ: PLXP) * PTC Therapeutics, Inc. (NASDAQ: PTCT) * Shockwave Medical Inc (NASDAQ: SWAV) * Sotera Health Co (NASDAQ: SHC) (began trading on Nasdaq Friday following its IPO) * Spero Therapeutics Inc (NASDAQ: SPRO) * Syndax Pharmaceuticals Inc (NASDAQ: SNDX) * TRACON Pharmaceuticals Inc (NASDAQ: TCON) (announced publication of data on its cancer treatment candidate TRC102) * Trinity Biotech plc (NASDAQ: TRIB) * Twist Bioscience Corp (NASDAQ: TWST) (reacted to fourth-quarter results) * Veracyte Inc (NASDAQ: VCYT)Down In The Dumps (Biotech Stocks Hitting 52-week Lows Nov. 23) * HTG Molecular Diagnostics (NASDAQ: HTGM) (began trading on a reverse split-adjusted basis) * Kiromic Biopharma Inc (NASDAQ: KRBP) * Maravai Lifesciences Holdings Inc (NASDAQ: MRVI) (debuted on Wall Street Friday) * Polarityte Inc (NASDAQ: PTE)Stocks In Focus DBV Announces Departure Of Chief Scientific Officer DBV Technologies ADR Representing 0.5 Ord Shs (NASDAQ: DBVT) announced that Dr. Hugh Sampson is stepping down from his role as chief scientific officer effective Dec. 1 to return to his research program at the Jaffe Food Allergy Institute at Mount Sinai.Sampson will take on a new role as scientific adviser to the CEO and chairman of DBV's Scientific Advisory Board, the company said.The stock was down 10.99% at $2.43 in premarket trading Tuesday.Novartis Details Sales, Pipeline, Margins At Investor Meeting Novartis AG (NYSE: NVS) said at its annual investor event that key growth drivers now contribute to 48% of innovative medicines sales. The company sees upcoming launches as fueling future sales expansion.Novartis said it is committed to driving consistent margin expansion, with margins at Innovative Medicines expected to reach the high 30s in the mid-term.The company also said its pipeline, including 116 assets in Phase 1 or 2 studies; 49 in Phase 3 studies or undergoing registration; and more than 65 new molecular entities will fuel growth in the mid-to long-term, with about 90% potential first-in-class/first-in-indication medicines and about 80% of targets in areas of high unmet patient need.The company also said it has initiated a stock buyback of up to $2.5 billion.The stock was up 0.27% to $87.55 in premarket trading Tuesday.ObsEva Submits App For Menstrual Bleeding Drug In Europe Obseva SA (NASDAQ: OBSV) said it has submitted to the European Medicines Agency a Marketing Authorization for linzagolix 100mg and linzagolix 200mg, to be used for the management of heavy menstrual bleeding associated with uterine fibroids.The company said it expects to submit an NDA to the FDA in the first half of 2021.In premarket trading Tuesday, ObsEva shares were rallying 6.8% to $2.04. Related Link: The Week Ahead In Biotech: Moderna Vaccine And Roche, Revance, Rhythm, Liquidia FDA Updates MediciNova Starts Intranasal COVID-19 Vaccine Manufacturing MediciNova, Inc. (NASDAQ: MNOV) said Master Virus Seed Stock production of its novel intranasal SARS-CoV-2 vaccine for COVID-19 has been initiated at Millipore Sigma BioReliance Services, a group company of Germany's Merck KGaA (OTC: MKGAF), using BC-PIV technology. "By infecting MVSS to the packaging cells, BC-PIV/S is produced, which is then recovered and purified to produce the BC-PIV SARS-CoV-2 vaccine for clinical studies," the company said.FDA OKs Alnylan's Oxluma For Primary Hyperoxaluria Type 1 The FDA approved Alnylam Pharmaceuticals, Inc.'s (NASDAQ: ALNY) Oxlumo as the first treatment for primary hyperoxaluria type 1, a rare genetic disorder.View more earnings on IBBThe NDA had a PDUFA action date of Dec. 3.PH1 is the most common and severe type of primary hyperoxalurias, a disorder caused by the excess production of oxalate, and affects an estimated one to three individuals per million in North America and Europe. It accounts for approximately 80% of PH cases.Last week, the company said the European drug regulator approved Oxluma for the same indication.Neuronetics Gets FDA Clearance For TouchStar Treatment Neuronetics said the FDA granted clearance for its TouchStar treatment, a 3-minute intermittent theta burst protocol with its NeuroStar Advanced Therapy System, administered with patented Contact Sensing technology.The stock gained 4.29% to $8.27 premarket. Bristol-Myers Squibb's Opdivo Approved For Gastroesophageal Cancer Bristol-Myers Squibb Co (NYSE: BMY) said the European Commission has approved Opdivo for the treatment of adults with unresectable advanced, recurrent or metastatic esophageal squamous cell carcinoma after prior fluoropyrimidine- and platinum-based combination chemotherapy.The stock was moving up 0.78% to $62.40 in premarket trading.KemPharm Issues Pipeline Update Providing an update to its prodrug development pipeline, KemPharm Inc (OTC: KMPH) said it expects to file an investigational new drug application for KP879, an agonist replacement therapy for the treatment of stimulant use disorder, before the end of 2020. The company also introduced a new prodrug candidate, KP1077, as a potential treatment for idiopathic hypersomnia.Earnings Enanta Pharmaceuticals Inc's (NASDAQ: ENTA) third-quarter revenue fell from $51.31 million to $23.63 million year-over-year. The company reversed from a profit of 44 cents per share to a loss of $1.46 per share. Analysts had estimated a narrower loss of 95 cents per share.The stock fell 4.85% to $41.55 in after-hours trading.Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) unexpectedly reversed to a loss in its fourth quarter.In after-hours trading, the stock was down 3.24% to $65.99.Offerings Advaxis, Inc. (NASDAQ: ADXS) said it intends to offer shares of its common stock and warrants to purchase shares of its common stock in an underwritten public offering.In after-hours trading, the stock fell 18.64% to 32 cents.On The Radar PDUFA Dates Liquidia Technologies Inc (NASDAQ: LQDA) awaits an FDA decision on its NDA for LIQ861, an investigational, inhaled dry powder formulation of Treprostinil for the treatment of pulmonary arterial hypertension.Earnings Medtronic PLC (NYSE: MDT) (before the market open)China Biologic Products Holdings Inc (NASDAQ: CBPO) (after the close)Related Link: Attention Biotech Investors: Mark Your Calendar For These November PDUFA Dates See more from Benzinga * Click here for options trades from Benzinga * The Daily Biotech Pulse: Amarin Surges On Vascepa Data, Mesoblast Rallies On Novartis Deal, Decision Day For Eiger * The Daily Biotech Pulse: Aquestive's Positive FDA Meeting, Prevail Awarded Patent, Neuro-Oncology Conference Gets Underway(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
On Tuesday, Swiss biopharma company Novartis AG (NYSE: NVS) announced a $2.5 billion share buyback program. The management also exhibited a heightened confidence level in its sales projections based on the current pipeline of products under development.What Happened: The buyback decision was spurred by a strong liquidity position along with the top ratings for its capital structure from companies like S&P (AA-) and Moody's (A1).CEO Vas Narasimhan said that management has "confidence in future growth and success of our pipeline." The share repurchase program will kick-off immediately and could continue till the first half of the next year.Novartis expects margins to widen due to cost reduction measures across the Technical Operations and Business Services units. These efforts could save close to $2 billion by the end of 2020. The management anticipates an additional cost savings of $2 billion from productivity programs in the Technical Operations unit.Why Does It Matter: Novartis management has high hopes from five of its assets in experimental medicines for cancer treatment, which could progress to the mid and late stages of trials next year. Six assets from the Pharmaceuticals unit are expected to reach key milestones between 2021 and 2022.Based on products under development, Novartis holds the second spot in the biopharma sector. The management anticipates substantial revenue growth in the future driven by these experimental treatments.Price Action: NVS shares are higher by 0.92% at $88.11 in the pre-market session on the last check Tuesday.Image Courtesy: WikimediaSee more from Benzinga * Click here for options trades from Benzinga * Snap Introduces TikTok-Like 'Spotlight' Video-Sharing Feature * JPMorgan Recommends Alternative Investment Strategies In Post-Pandemic Era(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.